Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PFSCF ProMetic Life Sciences	$5.47	$5.47	$5.47 ▼ $352.00	$127.45M	2.46	279 shs	N/A
PRME Prime Medicine	$3.57 -1.9%	$3.28	$1.11 ▼ $5.17	$480.43M	2.39	2.51 million shs	3.66 million shs
TERN Terns Pharmaceuticals	$7.05 +4.1%	$4.94	$1.87 ▼ $11.40	$616.95M	-0.05	1.17 million shs	1.84 million shs
UPXI Upexi	$7.35 -7.0%	$6.60	$1.90 ▼ $22.57	$656.80M	-0.52	3.60 million shs	6.47 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PFSCF ProMetic Life Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
PRME Prime Medicine	-4.46%	-1.09%	-15.15%	+128.93%	-11.44%
TERN Terns Pharmaceuticals	+4.31%	+20.04%	+34.06%	+135.07%	+4.31%
UPXI Upexi	+0.89%	+41.83%	+51.92%	-22.47%	+94.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	3.6895 of 5 stars	4.4	1.0	0.0	0.0	2.3	5.0	0.6
TERN Terns Pharmaceuticals	4.0292 of 5 stars	3.3	1.0	0.0	4.1	3.4	3.3	0.0
UPXI Upexi	2.8361 of 5 stars	3.8	2.0	0.0	0.0	2.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PFSCF ProMetic Life Sciences	0.00	N/A	N/A	N/A
PRME Prime Medicine	2.75	Moderate Buy	$8.92	149.77% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	121.63% Upside
UPXI Upexi	3.50	Strong Buy	$15.50	110.88% Upside

Current Analyst Ratings Breakdown

Latest PFSCF, UPXI, PRME, and TERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/4/2025	UPXI Upexi	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/16/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$16.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	PRME Prime Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/19/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PFSCF ProMetic Life Sciences	$36.55M	3.49	N/A	N/A	($67.63) per share	-0.08
PRME Prime Medicine	$4.96M	96.84	N/A	N/A	$1.37 per share	2.61
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$3.49 per share	N/A
UPXI Upexi	$26M	25.26	N/A	N/A	$6.24 per share	1.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PFSCF ProMetic Life Sciences	-$150.73M	N/A	0.00	∞	N/A	-894.02%	-3,350.55%	-67.76%	N/A
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A
TERN Terns Pharmaceuticals	-$88.85M	-$1.04	N/A	N/A	N/A	N/A	-27.35%	-26.18%	N/A
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	9/29/2025 (Estimated)

Latest PFSCF, UPXI, PRME, and TERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
5/16/2025	Q1 2025	UPXI Upexi	N/A	-$2.87	N/A	-$2.87	N/A	$3.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	40.50%	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PFSCF ProMetic Life Sciences	N/A	0.95	0.71
PRME Prime Medicine	N/A	6.50	6.50
TERN Terns Pharmaceuticals	N/A	24.70	24.70
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PFSCF ProMetic Life Sciences	0.10%
PRME Prime Medicine	70.37%
TERN Terns Pharmaceuticals	98.26%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
PFSCF ProMetic Life Sciences	N/A
PRME Prime Medicine	22.74%
TERN Terns Pharmaceuticals	1.50%
UPXI Upexi	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PFSCF ProMetic Life Sciences	50	23.31 million	N/A	Not Optionable
PRME Prime Medicine	234	134.57 million	100.38 million	Optionable
TERN Terns Pharmaceuticals	40	87.51 million	86.20 million	Not Optionable
UPXI Upexi	130	89.36 million	61.12 million	Optionable

PFSCF, UPXI, PRME, and TERN Headlines

Recent News About These Companies

Digital Asset Treasury Firms Plunge as Bitcoin Tumbles Below $117K, ETH Slides to $4.4K

2 hours ago | coindesk.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?

3 hours ago | marketbeat.com

Upexi establishes Advisory Committee, welcomes Hayes as first member

August 13 at 3:39 AM | msn.com

Former Amazon aggregator turns to Solana, records $70K in daily rewards

August 13 at 3:39 AM | msn.com

Upexi (NASDAQ:UPXI) Sees Unusually-High Trading Volume - Time to Buy?

August 12 at 3:43 PM | marketbeat.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)

August 11, 2025 | prnewswire.com

Upexi (NASDAQ:UPXI) Shares Up 14.2% - Here's What Happened

August 9, 2025 | marketbeat.com

Crypto Currents: SEC eases staking rules as bitcoin miners pivot to AI

August 6, 2025 | msn.com

Alliance Global Partners Begins Coverage on Upexi (NASDAQ:UPXI)

August 6, 2025 | americanbankingnews.com

Upexi Surpasses 2 Million SOL in its Treasury

August 5, 2025 | taiwannews.com.twT

Solana Treasury Company Upexi Surpasses 2M in SOL Holdings

August 5, 2025 | coindesk.com

Upexi (NASDAQ:UPXI) Earns Buy Rating from Analysts at Alliance Global Partners

August 5, 2025 | marketbeat.com

Upexi, Inc. (NASDAQ:UPXI) Director Gene Salkind Buys 20,243 Shares

July 31, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 20,243 Shares of Stock

July 31, 2025 | insidertrades.com

Upexi (NASDAQ:UPXI) Stock Price Down 9.9% - What's Next?

July 31, 2025 | marketbeat.com

Upexi to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 12th-14th

July 30, 2025 | manilatimes.netM

Upexi Secures $500M Equity Deal to Buy More Solana Despite Stock Drop

July 30, 2025 | thecurrencyanalytics.comT

Upexi enters $500M equity line agreement

July 29, 2025 | msn.com

Upexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury Strategy

July 29, 2025 | manilatimes.netM

Solana Treasury firm Upexi secures $500M to acquire more SOL

July 29, 2025 | msn.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Here's Why

July 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSCF, UPXI, PRME, and TERN Company Descriptions

ProMetic Life Sciences OTCMKTS:PFSCF

$5.47 0.00 (0.00%)

As of 11/18/2019

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Prime Medicine NYSE:PRME

$3.57 -0.07 (-1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$3.60 +0.03 (+0.84%)

As of 04:30 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Terns Pharmaceuticals NASDAQ:TERN

$7.05 +0.28 (+4.14%)

Closing price 04:00 PM Eastern

Extended Trading

$7.04 -0.01 (-0.14%)

As of 04:22 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Upexi NASDAQ:UPXI

$7.35 -0.55 (-6.96%)

Closing price 04:00 PM Eastern

Extended Trading

$7.36 +0.01 (+0.07%)

As of 04:36 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time